Improved in vitro biocompatibility of bicarbonate-buffered peritoneal dialysis fluid

Peritoneal Dialysis International

Volumn 26, Issue 6, 2006, Pages 664-670

  Grossin, Nicolas ^a   Wautier, Marie Paule ^b   Wautier, Jean Luc ^a,c   Gane, Pierre ^b   Taamma, Redouane ^d   Boulanger, Eric ^a,e  

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Fresenius Medical Care   (France)

^e Centres Hospitaliers Univ Grenoble   (France)

Author keywords

Biocompatibility; Glycoxidation; Mesothelial cell

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BUFFER; GLUCOSE DEGRADATION PRODUCT; GLYCOSYLATED PROTEIN; PERITONEAL DIALYSIS FLUID; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

APOPTOSIS; ARTICLE; BIOCOMPATIBILITY; CARCINOGENESIS; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; HEMODIALYSIS PATIENT; HUMAN; IMMUNOASSAY; IN VITRO STUDY; MESOTHELIUM CELL; PERITONEAL DIALYSIS; PERITONEUM; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY;

EID: 33846698905     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080602600610     Document Type: Article

References (23)

1. Margetts P, Kolb M, Yu L, Hoff C, Holmes C, Anthony D, et al. Inflammatory cytokines, angiogenesis, and fibrosis in the rat peritoneum. Am J Pathol 2002; 160:2285-94.
2. Combet S, Miyata T, Moulin P, Pouthier D, Goffin E, Devuyst O. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis. J Am Soc Nephrol 2000; 11:717-28.
3. Witowski J, Bender T, Wisniewska-Elnur J, Ksiazek K, Passlick-Deetjen J, Breborowicz A, et al. Mesothelial toxicity of peritoneal dialysis fluids is related primarily to glucose degradation products, not to glucose per se. Perit Dial Int 2003; 23:381-90.
4. Welten A, Schalkwijk C, ter Wee P, Meijer S, van den Born J, Beelen R. Single exposure of mesothetial cells to glucose degradation products (GDPs) yields early advanced glycation end-products (AGEs) and a proinflammatory response. Perit Dial Int 2003; 23:213-21.
5. Wieslander A, Linden T, Kjellstrand P. Glucose degradation products in peritoneal dialysis fluids: how they can be avoided. Perit Dial Int 2001; 21(Suppl 3):S119-24.
6. Erixon M, Linden T, Kjellstrand P, Carlsson O, Ernebrant M, Forsback G, et al. PD fluids contain high concentrations of cytotoxic GDPs directly after sterilization. Perit Dial Int 2004; 24:392-8.
7. Linden T, Cohen A, Deppisch R, Kjellstrand P, Wieslander A. 3,4-dideoxyglucosone-3-ene (3,4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis. Kidney Int 2002; 62:697-703.
8. Boulanger E, Wautier MP, Gane P, Mariette C, Devuyst O, Wautier JL. The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products. Nephrol Dial Transplant 2004; 19: 2208-16.
9. Boulanger E, Wautier M, Wautier J, Boval B, Panis Y, Wernert N, et al. AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int 2002; 61: 148-56.
10. Boulanger E, Moranne O, Wautier M, Witko-Sarsat V, Descamps-Latscha B, Kandoussi A, et al. Changes in glycation and oxidation markers in patients starting peritoneal dialysis: a pilot study. Perit Dial Int 2006; 26:207-12.
11. Tauer A, Knerr T, Niwa T, Schaub TP, Lage C, Passlick-Deetjen J, et al. In vitro formation of N(epsilon)-(carboxy-methyl) lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis. Biochem Biophys Res Commun 2001; 280:1408-14.
12. Mortier S, Faict D, Schalkwijk C, Lameire N, De Vriese A. Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 2004; 66: 1257-65.
13. Thornalley PJ. The enzymatic defence against glycation in health, disease and therapeutics: a symposium to examine the concept. Biochem Soc Trans 2003; 31:1341-2.
14. Zareie M, Keuning E, ter Wee P, Schalkwijk C, Beelen R, van den Born J. Improved biocompatibility of bicarbonate/lactate-buffered PDF is not related to pH. Nephrol Dial Transplant 2006; 21:208-16.
15. Tauer A, Zhang X, Schaub T, Zimmec T, Niwa T, Passlick-Deetjen J, et al. Formation of advanced glycation end products during CAPD. Am J Kidney Dis 2003; 41(3 Suppl 1):S57-60.
16. De Vriese AS, Flyvbjerg A, Mortier S, Tilton RG, Lameire NH. Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. J Am Soc Nephrol 2003; 14:2109-18.
17. Inagi R, Miyata T, Yamamoto T, Suzuki D, Urakami K, Saito A, et al. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett 1999; 463:260-4.
18. Mandl-Weber S, Cohen C, Haslinger B, Kretzler M, Sitter T. Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells. Kidney Int 2002; 61:570-8.
19. Devuyst O, Nielsen S, Cosyns J, Smith B, Agre P, Squifflet J, et al. Aquaporin-1 and endothelial nitric oxide synthase expression in capillary endothelia of human peritoneum. Am J Physiol 1998; 275:H234-H242.
20. Topley N. Peritoneal dialysis solution biocompatibility testing: a realistic alternative? Perit Dial Int 2005; 25: 387-93.
21. Haas S, Schmitt C, Arbeiter K, Bonzel K, Fischbach M, John U, et al. Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis. J Am Soc Nephrol 2003; 14:2632-8.
22. Montenegro J, Saracho R, Martínez I, Muñoz R, Ocharan J, Valladares E. Long-term clinical experience with pure bicarbonate peritoneal dialysis solutions. Perit Dial Int 2006; 26:89-94.
23. Feriani M. Use of different buffers in peritoneal dialysis. Semin Dial 2000; 13:256-60.